ZAMBON, Alfonso
 Distribuzione geografica
Continente #
NA - Nord America 13.189
EU - Europa 5.818
AS - Asia 5.525
SA - Sud America 808
Continente sconosciuto - Info sul continente non disponibili 171
AF - Africa 144
OC - Oceania 10
Totale 25.665
Nazione #
US - Stati Uniti d'America 12.859
IT - Italia 1.728
SG - Singapore 1.702
CN - Cina 1.255
GB - Regno Unito 1.106
HK - Hong Kong 976
DE - Germania 795
SE - Svezia 646
BR - Brasile 606
VN - Vietnam 570
PL - Polonia 279
BD - Bangladesh 266
FR - Francia 246
RU - Federazione Russa 222
FI - Finlandia 198
CA - Canada 167
UA - Ucraina 164
KR - Corea 161
IN - India 124
ID - Indonesia 96
NL - Olanda 79
BG - Bulgaria 77
MX - Messico 71
TR - Turchia 71
AR - Argentina 59
JP - Giappone 50
IE - Irlanda 47
ES - Italia 43
EC - Ecuador 40
BE - Belgio 37
IQ - Iraq 35
CO - Colombia 34
ZA - Sudafrica 33
MA - Marocco 31
MY - Malesia 30
AT - Austria 29
VE - Venezuela 27
AE - Emirati Arabi Uniti 23
PK - Pakistan 22
IR - Iran 21
JM - Giamaica 17
CH - Svizzera 16
RO - Romania 16
DZ - Algeria 15
EG - Egitto 15
LT - Lituania 15
TH - Thailandia 15
CL - Cile 13
UZ - Uzbekistan 13
CR - Costa Rica 12
KE - Kenya 12
PH - Filippine 12
TN - Tunisia 12
CZ - Repubblica Ceca 11
PY - Paraguay 11
SA - Arabia Saudita 11
TT - Trinidad e Tobago 11
IL - Israele 10
PT - Portogallo 9
AU - Australia 8
HN - Honduras 8
LK - Sri Lanka 8
PE - Perù 8
BY - Bielorussia 7
DO - Repubblica Dominicana 7
GE - Georgia 7
JO - Giordania 7
NI - Nicaragua 7
SV - El Salvador 7
EE - Estonia 6
HU - Ungheria 6
RS - Serbia 6
AZ - Azerbaigian 5
DK - Danimarca 5
ET - Etiopia 5
GT - Guatemala 5
KZ - Kazakistan 5
LB - Libano 5
NP - Nepal 5
SC - Seychelles 5
AL - Albania 4
BO - Bolivia 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
AO - Angola 3
BB - Barbados 3
BZ - Belize 3
KG - Kirghizistan 3
LU - Lussemburgo 3
OM - Oman 3
PA - Panama 3
PR - Porto Rico 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BS - Bahamas 2
CY - Cipro 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
Totale 25.461
Città #
Ashburn 1.458
Santa Clara 1.154
Singapore 1.112
Fairfield 1.030
Hong Kong 949
San Jose 682
Woodbridge 629
Southend 576
Chandler 568
Houston 501
Modena 492
Ann Arbor 439
Council Bluffs 412
Seattle 387
Cambridge 386
Nyköping 384
Hefei 372
Frankfurt am Main 350
Wilmington 330
London 295
Warsaw 257
Beijing 256
Jacksonville 228
Dearborn 222
Los Angeles 212
Chicago 191
Ho Chi Minh City 191
Dallas 177
Helsinki 176
The Dalles 155
New York 149
Hanoi 147
Seoul 140
Berlin 106
Bologna 104
San Diego 88
Milan 77
Boardman 76
Princeton 76
Reggio Emilia 74
Sofia 74
Bremen 73
Buffalo 67
Eugene 65
Lauterbourg 65
Jakarta 63
Columbus 61
São Paulo 61
Moscow 60
Salt Lake City 60
Orem 53
Munich 46
Atlanta 42
Dublin 42
Rome 40
Shanghai 40
Toronto 38
Tokyo 37
Parma 35
Phoenix 35
Redondo Beach 34
Formigine 33
Amsterdam 32
Brussels 32
Denver 32
Izmir 31
Redwood City 31
Da Nang 30
Montreal 30
Tampa 27
Newark 26
Stockholm 25
Chennai 24
Turin 24
Washington 24
Brooklyn 22
Vancouver 22
Wimbledon 22
Bomporto 21
Kent 21
Rio de Janeiro 21
Elk Grove Village 20
North Bergen 20
Norwalk 20
Falls Church 19
Mexico City 17
Nuremberg 17
Saint Augustine 17
Voghera 17
Belo Horizonte 16
Des Moines 16
Johannesburg 16
Lappeenranta 16
Paris 16
Florence 15
Guangzhou 15
Haiphong 15
Madrid 15
Manchester 15
Naples 15
Totale 17.546
Nome #
1 - ( 5 - TERT - BUTYL - 2 - ARYL - PYRAZOL - 3 - YL ) . 3 - 12 - FLUORO - 4 - [ ( 3 - OXO - 4H - PYRIDO [ 2 . 3 - BJPYRAZIN - 8 - YL ) OXY | PHENYLJUREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER 1.058
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships 626
Chiral polycyclic ketones via desymmetrization of dihaloolefins 482
Potential of wickerhamomyces anomalus in glycerol valorization 463
Cytocompatibility of potential bioactive cerium-doped glasses based on 45S5 420
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling 393
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma 393
Nucleoside 2’,3’-cyclic monophosphates in Aphanizomenon flos-aquae detected through nuclear magnetic resonance and mass spectrometry 364
A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors 360
A novel mechanism for the fluxional behaviour of [Pd(η2-tetramethylethylenetetracarboxylate)(2-methylthiomethylpyridine)] 358
Mesoporous bioactive glasses doped with cerium: Investigation over enzymatic-like mimetic activities and bioactivity 350
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 349
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF 347
BRAF as a therapeutic target: A patent review (2006-2012) 347
Cerium Containing Bioactive Glasses: A Review 347
Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations 344
Boosting sunscreen stability: New hybrid materials from UV filters encapsulation 344
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring 341
Assessment of chloroaniline toxicity by the submitochondrial particle assay 337
Structure Model and Toxicity of the Product of Biodissolution of Chrysotile Asbestos in the Lungs 337
1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy 331
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): Increasing cellular potency through optimization of a distal heteroaromatic group 330
Investigation on the antimicrobial properties of cerium-doped bioactive glasses 318
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors 315
Ce-MBGs Loaded with Gentamicin: Characterization and In Vitro Evaluation 304
β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics 304
Thiophene based A-D-A small molecules with a dithienosilole core: synthesis, theoretical calculations and optoelectronic properties 292
The discovery of novel, highly potent inhibitors of BRAF 290
Development and exploitation of CK2 inhibitors 289
Synthesis and evaluation of new chiral diols based on the dicyclopentadiene skeleton 288
1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-2-FLUORO-4-(3-OXO-4H-PYRIDO2,3-BPYRAZIN-8-YL)OXYPHENYLUREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER 286
Non canonical Cyclic Nucleotides Monophosphates in Aphanizomenon flosaquae: nuclear magnetic resonance and mass spectrometry 278
Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring 273
"Hexacarboxytrindanes": Benzene rings with homotopic faces as scaffolds for the construction of D3 chiral architectures 270
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 268
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) 267
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents 267
Bifunctional mesoporous glasses for bone tissue engineering: Biological effects of doping with cerium and polyphenols in 2D and 3D in vitro models 266
Tris-annelated benzenes selectively perfunctionalized on one side only: Hexachlorobenzotrinorbornadiene as a versatile scaffold for the construction of molecular domes 266
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds 262
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors 262
Substituted aniline interaction with submitochondrial particles and quantitative structure-activity relationships 260
Gatekeeper mutations mediate resistance to BRAF-targeted therapies 259
Study on the toxicity of phenolic and phenoxy herbicides using the submitochondrial particle assay 257
Surface acidity modifications induced by thermal treatments and acid leaching on microcrystalline H-BEA zeolite. A FTIR, XRD and MAS-NMR study 255
Synthesis of the syn and anti isomer of 1,4,5,8,9,12-hexahydro-2,3,6,7,10,11-hexamethylidene-1,4 : 5,8 : 9,12-trimethanotriphenylene and Diels-Alder reactivity of the syn isomer 245
Efficient access to 5-substituted thiazoles by a novel metallotropic rearrangement 243
Internal motions in a fulleropyrrolidine tertiary amide with axial chirality 242
Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor–Induced Cutaneous Squamous Cell Carcinoma 242
Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives 241
Novel oligothiophenes with reduced HOMO-LUMO band gap for Optoelectonics 241
Loading with Biomolecules Modulates the Antioxidant Activity of Cerium-Doped Bioactive Glasses 239
Isolation and characterization of all eight bisadducts of fulleropyrrolidine derivatives 236
Non-canonical Cyclic Nucleoside Monophosphates in Aphanizomenon flos-aquae: nuclear magnetic resonance and mass spectrometry 236
ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF 231
Synthetic approach to novel NMP/ALK inhibitors 230
Small molecule inhibitors of BRAF in clinical trials 227
Nucleophilic reactions at the ring carbons of thiiranium and thiirenium ions. An experimental and theoretical comparison of the S(N)2 and S(N)2-Vin mechanisms 226
Efficient cyclotrimerization of bicyclic vic-bromostannylalkenes promoted by copper(I) thiophen-2-carboxylate 224
Dual Kinase Targeting in Leukemia 224
Cytocompatibility of mesoporous bioactive glasses doped with cerium and loaded with polyphenols 222
ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF 222
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma 220
Evaluation of the Properties of Bioactive Mesoporous Glasses Doped with Cerium and Loaded with Polyphenols 216
Expedient Access to Type II Kinase Inhibitor Chemotypes by Microwave-Assisted Suzuki Coupling 216
Qualitative and quantitative discrimination of fake and true alkene rotation processes in pd(η2-olefin) complexes. A new bimolecular mechanism 215
Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis 210
Rational design of inhibitors of the anaplastic lymphoma kinase 203
Biostimulants derived from organic urban wastes and biomasses: An innovative approach 202
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 201
Double-ion doped mesoporous glasses: Studies on stability, antibacterial and antioxidant properties, and bioactivity 200
Evaluation of the behaviour of hydrogels containing mesoporous glasses doped with cerium and loaded with polyphenols 198
LYSYL OXIDASE INHIBITORS 198
α‐Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML 193
Erratum: Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase (ACS Omega (2022) 7:20 (17083-17097) DOI: 10.1021/acsomega.2c00507) 187
Extraction, purification and in vitro assessment of the antioxidant and anti-inflammatory activity of policosanols from non-psychoactive Cannabis sativa L. 184
NON CANONICAL CYCLIC NUCLEOTIDES MONOPHOSPHATES IN APHANIZOMENON FLOS-AQUAE: NUCLEAR MAGNETIC RESONANCE AND MASS SPECTROMETRY 183
Dual loaded Ce-MBGs with bioactivity, antioxidant and antibacterial properties 183
Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow 179
Preparation of 1-​(5-​tert-​butyl-​2-​aryl-​pyrazol-​3-​yl)​-​3-​[2-​fluoro-​4-​[(3-​oxo-​4H-​pyrido[2,​3-​b]​pyrazin-​8-​yl)​oxy]​phenyl]​urea derivatives as RAF inhibitors for treating cancer 173
endo-1-Phenylborneol as a novel, alternative chiral auxiliary for the aza-Diels-Alder reaction 173
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 163
Novel ligands from direct benzylic functionalisation of tris(2-pyridylmethyl)amine 160
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 153
PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H PYRIDO2,3-B PYRAZIN-3-ONE DERIVATIVES 148
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers 147
Materiale fotoassorbente ad ampio spettro, procedimento per la sua preparazione ed usi relativi 145
Polyphosphate coacervate gels for manufacturing of manganese loaded glass powders and fibres: structural, cytocompatibility and surface bioactivity study 140
Erratum: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (Cancer Cell (2015) 27(1) (85–96) (S1535610814004577) (10.1016/j.ccell.2014.11.006)) 135
Long-term durability of discarded cork-based composites obtained by geopolymerization 133
Corrections to pyridoimidazolones as novel potent inhibitors of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) (Journal of Medicinal Chemistry (2009) 52, (2255-2256) DOI: 10.1021/jm801509w) 128
Targeting monocarboxylate transporter 1 with a copper-chelating coumarin-based bioconjugate: Synthesis and characterization 127
Dual-functional cerium-containing mesoporous bioactive glasses for drug delivery 123
Enhanced bone regeneration with cerium-doped bioactive glasses: In vitro and in vivo study 114
Erratum: Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma (Journal of Investigative Dermatology (2013) 133 (274-276) DOI: 10.1038/jid.2012.268;0 113
Gelatin/Cerium-Doped Bioactive Glass Composites for Enhancing Cellular Functions of Human Mesenchymal Stem Cells (hBMSCs) 111
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 110
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 108
Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia 89
Negative Allosteric Modulators of A2AR: A New Weapon for Cancer Immunotherapy? 82
Totale 25.551
Categoria #
all - tutte 92.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.300


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.160 0 0 0 58 73 89 99 82 188 96 288 187
2022/20231.967 245 218 134 187 258 249 71 176 246 46 76 61
2023/20241.625 52 94 110 97 514 43 278 178 43 48 52 116
2024/20254.053 126 43 125 203 806 566 214 319 564 224 398 465
2025/20268.274 425 326 694 901 1.077 999 887 422 736 765 634 408
2026/20272.454 325 722 558 849 0 0 0 0 0 0 0 0
Totale 25.665